Pharmacokinetics and pharmacodynamics of cannabigerol (CBG) in the C57BL/6Crl mouse.

ABSTRACT:

Introduction

Cannabis holds therapeutic potential; however, activation of the type 1 cannabinoid receptor (CB1R) via Δ^9-tetrahydrocannabinol (THC) is also responsible for the characteristic "high" induced by cannabis. The pharmacology of the less abundant phytocannabinoid, cannabigerol (CBG), is poorly established, though it has been shown to exhibit promising therapeutic properties such as potential anxiolytic effects.

Methods

We assessed the pharmacokinetics (PK) and pharmacodynamics (PD) of CBG in C57BL/6Crl mice, hypothesizing that CBG would produce fewer PD effects than we had previously observed with THC, even when accounting for PK differences. Following oral (p.o.), intraperitoneal (i.p.), and intravenous (i.v.) administration, the PK

SUBMITTER: Zagzoog A 

PROVIDER: S-EPMC12722920 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature